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In recent months, as South Africa (SA) approaches the peak of 
SARS-CoV-2 infections, there has been increasing debate on the 
potential clinical and public health utility of serological tests in 
the COVID-19 pandemic. This discussion – which has recently 
played out vocally in the literature and in the media[1-3] – has arisen 
in part due to well-documented limitations in the availability and 
turnaround times of polymerase chain reaction (PCR)-based tests, 
and in part due to the clamour for access to tools that may best 
gauge the true prevalence of SARS-CoV-2 infection in SA, and the 
possibility of identifying people who may now be immune to future 
SARS-CoV-2 infection. More than 370 COVID-19 serological tests 
are now commercially available or in development worldwide,[4] 
many of which have been put forward for a potential market in 
SA. Although one such test has recently been approved for local 
use, the question remains: why has there not been more rapid local 
regulatory endorsement and widespread adoption of serological 
testing in SA as a useful tool in the current pandemic? It can 
be explained in terms of two fundamental factors: our evolving 
understanding of the dynamics of adaptive immune responses to 
SARS-CoV-2 infection, and the ingredients required for a good 
serological test. We will focus on some of the complexities involved 
in considering assay performance and how best to use COVID-19 
antibody testing in the SA pandemic.
Recent research
Impact of time-dependent adaptive immune responses 
following SARS-CoV-2 infection
As described in Box 1, most COVID-19 serological tests measure 
pathogen-specific antibody responses following acute viral infection. 
Key emerging immunity in SARS-CoV-2-infected people that 
underpins serological testing is highlighted in Fig. 1. 
• Antibody responses can target multiple viral antigens and epitopes, 
and these may differ between individuals. Dominant antibody 
responses to SARS-CoV-2 appear to be directed to epitopes 
within either spike (S) protein or the nucleocapsid (N) protein, 
although antibodies against envelope and membrane proteins can 
be detected.
• The antibodies that develop in response to infection can be either 
binding or neutralising (Fig. 1A). Neutralising antibodies interfere 
with the interaction between virus (the S protein) and host cell 
(angiotensin-converting enzyme 2 receptors), preventing viral 
entry, or can be involved in antibody-dependent cell-mediated 
phagocytosis and/or cytotoxicity through Fc receptor-dependent 
pathways. In contrast, non-neutralising antibodies bind specifically 
to virions, but do not interfere with their infectivity. The S protein 
is the target of many serological assays, which detect both binding 
and neutralising antibodies but do not currently give an indication 
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of function. Lab-based cellular assays are therefore required 
to evaluate whether anti-SARS-CoV-2 antibodies in individual 
samples have Fc effector function and/or neutralising activity[6,7] 
and reflect the differing types of antibodies involved in protection. 
However, rapid point-of-care antibody tests do not discriminate 
between binding and neutralising function and therefore may not 
be used to measure protective immunity.
• A primary antibody response to any new viral infection takes 
time to develop and is never static, with antibody titres rising 
over a period of several weeks post onset of symptoms and then 
starting to wane. Fig. 1B depicts the initial peak responses of 
immunoglobulin M (IgM), followed by IgG and IgA isotypes. 
Responses to differing viral proteins seem to have very similar 
timing.[8] Notably, seroconversion following SARS-CoV-2 infection 
is detectable in <50% of symptomatic individuals 5 - 7 days post 
symptom onset, even using highly sensitive immunofluorescence 
assays, which coincides with when the majority of infected 
individuals become least infectious.[9]
• Although IgM or IgG is detectable in 90% of infected individuals 
14 - 16 days post symptom onset, at this stage almost none of these 
individuals are infectious (i.e. shedding live virus).[10]
• The magnitude of individual antibody responses following SARS-
CoV-2 infection may vary 100-fold, with disease severity emerging 
as a strong predictor of higher titres.[10] Further research is required 
to dissect out the relevance of other known factors on antibody 
responses, such as age, gender and immunosuppression, e.g. with 
HIV co-infection.
• Antibody responses to SARS-CoV-2 can wane rapidly during the 
weeks following infection, especially in mild or asymptomatic 
cases. Although longitudinal studies beyond 100 days are ongoing, 
recent studies have demonstrated rapid waning of all isotypes 
of antiviral antibodies, with longer persistence of detectable IgG 
following severe COVID-19 disease (3 months) compared with 
mild disease (1 month) (Fig. 1C).[8,10] The implications of this 
finding for interpretation of serological test data are discussed 
further below.
• Emerging data also suggest an apparent disconnect in some 
individuals who mount cytotoxic T-lymphocyte responses to 
SARS-CoV-2, but not a corresponding detectable antibody 
response.[11] Such individuals may represent those who do not 
seroconvert following what was probably mild infection or whose 
T-cell response is robust enough to clear infection prior to 
seroconversion. Further research is needed to determine whether 
such individuals possess a genetic underpinning of innate or 
adaptive immunity mechanisms that confers resistance to infection 
without seroconversion and how this relates to future risk of 
re-infection, disease severity and viral transmission.
Evaluating the sensitivity and specificity of COVID-19 
antibody tests: What constitutes a worthwhile test?
Since the start of the COVID-19 pandemic, numerous articles 
have been published comparing claimed and real-world clinical 
performance of antibody tests in seroprevalence studies. Typically, 
independent real-life performance appears less impressive than 
manufacturer-reported data, perhaps owing to patient selection 
bias towards hospitalised patients with severe disease during test 
development. A recent meta-analysis of 40 studies on COVID-19 
serological tests reported in preprints or peer-reviewed publications 
since January 2020 reinforces this, finding that the average sensitivity 
of enzyme-linked immunosorbent assays (ELISAs) or lateral 
flow assays (LFAs) measuring IgM or IgG was ~66% and ~84%, 
respectively, while average specificity of ELISAs and LFAs ranged 
from 96% to >99%, with a high risk of patient selection bias being 
found in the majority of studies.[12] It is important also to appreciate 
that ~7 - 14 days after SARS-CoV-2 infection, an IgM response will 
occur that can then switch to IgA and IgG in most people after 2 - 
3 weeks of infection. The sensitivity of antibody testing is therefore 
dependent on gaining samples during different window periods of 
infection. If the window of testing for IgM, IgA or IgG is at the onset 
of symptoms, this would bias the sensitivity to IgM. More commonly, 
as it is easier to accrue samples, if testing is performed 2 - 3 weeks 
after symptoms (and possibly 4 weeks after initial infection), this 
would bias sensitivity away from IgM and towards IgG (Fig. 1).
This time-dependency of class-specific antibody responses is 
reflected by meta-analyses showing that in the first week post onset 
of symptoms (POS), clinical sensitivity of IgG-specific ELISAs and 
LFAs is typically poor (~24% and ~13%, respectively), improving 
to 65% and 50%, respectively, at week 2 and to 82% and 80%, 
respectively, at week 3.[12] In addition, new evidence is emerging 
that low-titre antibody responses in convalescent individuals can 
Box 1. Distinguishing serological tests for COVID-19
COVID-19 antigen tests. Use immobilised antibodies to directly 
detect SARS-CoV-2 virus or viral antigens in a sample. In 
principle, a good direct antigen test could be a functional 
alternative to polymerase chain reaction-based testing that 
would work from onset of symptoms and at point of care (POC) 
in low-resource settings. However, in practice, developing 
these tests has not proved straightforward, owing to challenges 
in identifying and validating the pairs of antibodies that are 
required to provide high affinity and specificity detection of low 
levels of antigen.
COVID-19 antibody tests. These are currently more commonly 
available than direct antigen tests and come in different formats, 
including the simple and relatively cheap, qualitative lateral flow 
assays (otherwise known as ‘rapid antibody tests’) that can be 
used at POC or in field settings, and more accurate, quantitative 
lab-based enzyme-linked immunosorbent assays. These tests use 
immobilised SARS-CoV-2 antigens which allow the detection of 
circulating antibodies in plasma, serum or whole blood. Different 
COVID-19 antibody tests typically detect immunoglobulin G 
(IgG) and/or IgM antibodies to either the SARS-CoV-2 spike (S) 
protein (in either full-length trimeric form, or the isolated S1 or 
receptor binding domains), or the nucleocapsid (N) protein:
• The S protein is intuitively attractive for use in serological tests 
since it is directly involved in angiotensin-converting enzyme 2 
receptor binding during viral entry, which therefore makes it a 
target for the host response – mounting either neutralising or 
binding antibodies that target epitope regions in spike.
• However, in the SARS-CoV-1 outbreak of 2003, a significantly 
higher frequency of infected individuals had anti-N compared 
with anti-S antibodies,[5] potentially making assays based on the 
N protein attractive for seroprevalence studies in the current 
pandemic.
While many manufacturers do not disclose the precise identity of 
the target viral antigens used in their COVID-19 antibody tests, it 
is clear that at least some have engineered the target viral antigens 
to optimise performance. It is therefore important to appreciate 
that not all COVID-19 antibody tests are equivalent, especially 
where the antigen used is key to its clinical performance and 
utility. 
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wane more quickly than expected. One recent report showed that 
the percentage of PCR-positive, hospitalised COVID-19 cases with 
potent neutralising antibody titres dropped from 60% at 3 weeks POS 
to 17% at 65 days POS.[8] Similarly, another recent article reported 
that virus-specific IgG-positive proportions for symptomatic and 
asymptomatic individuals in their cohort were 84% and 81%, 
respectively, in the acute phase, but dropped to 73% and 49%, 
respectively, in the early convalescent phase (defined as 8 weeks after 
discharge from hospital).[10]
Our own recent studies on a cross-sectional SA cohort of 
convalescent COVID-19 cases (including asymptomatic, mild and 
severe cases; samples collected 3 - 4 weeks post first positive PCR 
test) identified virus-specific IgG titres of varying magnitudes in 
~65% of individuals (Blackburn et al., unpublished data). These 
findings suggest that some individuals in this cohort may never 
have generated a virus-specific IgG response, while in others the 
response may have waned very quickly, with no simple correlation 
with disease severity being observed. Longitudinal data are key to the 
interpretation of such variable antibody responses.
Why is all of this important? To avoid the detection of false 
negatives, we need to know the performance characteristics for 
measuring all antibody isotype responses to SARS-CoV-2. This not 
only speaks to the quality of detection, but also to knowledge about 
when the testing kits can be used at a given stage of infection and 
with what sensitivity. This is also a balancing act with specificity – 
which needs to be high enough to avoid false-positive responses due 
to cross-reactivity with conserved antigens across the coronavirus 
family. High sensitivity and specificity will be of critical importance 
for seroprevalence studies, as well as for studies that aim to determine 
the extent and durability of immunity in the SA population; research 
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Fig. 1. Emerging biology of antibody responses to SARS-COV-2 infection and relevance to serology. Cross-sectional and limited longitudinal studies of 
antibody responses to SARS-CoV-2 infection are published or in pre-print. The major SARS-CoV-2 viral proteins targeted by antibodies are shown in (A), 
several of which are targets of available serological assays. Targeted antibodies may be functional or non-functional, and this is not necessarily evident 
from serological test outputs. Different isotype responses against viral epitopes have differing kinetics, shown in (B), adapted using published enzyme-linked 
immunosorbent assay data from Seow et al.;[8] IgM and IgG are the major isotypes targeted in current serology. Antibody kinetics and adaptive responses to 
different COVID-19 disease severity will determine the best possible performance of an ideal serological test, and this is modelled in (C) given our current 
understanding. (ACE2R = angiotensin-converting enzyme 2 receptor; S1 and S2 = spike protein 1 and 2; RBD = receptor-binding domain of the spike protein; 
POS = point of symptom onset; *Arbitrary units (optical density at 1:50 dilution – this is not an absolute scale, since it depends on the precise assay set-up).)
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is therefore urgently needed on longitudinal cohorts in SA in order 
to be able to model these effects more accurately. Furthermore, it 
is also critical to evaluate these serological tests thoroughly prior to 
implementation and to adhere to scientific rigour in the approval 
process.
Discussion
From our knowledge of how immunity to acute viral infections 
develops and the range of individual test characteristics described 
above, the clinical application of serological assays needs to be 
considered carefully depending on the question being asked.
Can we identify acute infections?
Irrespective of test accuracy, the kinetics of antibody response make 
the use of serology for the diagnosis of acute infection very limited. 
In severe disease, antibody responses are likely to appear after 
treatment decisions need to be made, even in situations where PCR-
based testing is a false negative. Emerging data around infectivity 
in mild disease suggest that serology results are likely to be positive 
only after individuals are no longer infectious.[9] Multisystem-
inflammatory syndrome in children[13] may be the one exception, 
where linking the inflammatory picture to a recent SARS-CoV-2 
infection through detection of particular IgM responses may aid 
diagnosis and management.
Can we confirm recent or past infections?
Individuals. There is undoubtedly a major role for serological assays 
in SARS-CoV-2 infection, but owing to both the varied immune 
response between people and variable test performance character-
istics, applications are not so straightforward at the individual level. 
The majority of PCR-positive patients with SARS-CoV-2 infection 
produce a measurable antibody response, irrespective of disease 
severity. As discussed above, this may be detectable in the first 2 weeks 
after infection, but only in any reliable way >2 weeks following the start 
of symptoms.[12] Importantly, however, the rapid waning of antibody 
titres during convalescence means that a negative result does not imply 
absence of prior infection. This may have implications for individuals 
interacting with employers or insurers requiring evidence of infection, 
as well as people wishing to return to interacting with vulnerable family 
members or other communities after an unconfirmed but suspected 
SARS-CoV-2-related respiratory tract infection. For individual 
diagnosis, ensuring that serological testing is performed in the best 
time window after an acute illness (possible between 3 and 6 weeks) 
and using a test optimised for sensitivity (thereby reducing false-
negative results) is critical to get right.
Population. This is undoubtedly the major role for serological 
assays in SARS-CoV-2. Serological assays may have several public 
health applications, and we have already seen a number of recent 
seroprevalence publications from countries with substantial outbreaks. 
Such reports typically suggest seroprevalence to be orders of magnitude 
(5 - 50-fold) higher than PCR-proven cases: for example, one report 
estimated that up to 23% of individuals in New York City may have 
been infected,[14] while other reports found an average seroprevalence 
of 5% in Spain, with a higher prevalence around Madrid (>10%) and a 
lower prevalence in coastal areas (<3%).[15] In all cases, however, these 
reports suggest a very large remaining vulnerable population. A  key 
issue again here is that with waning of antibody titres, such cross-
sectional studies are only really able to estimate what the prevalence was 
1 - 3 months earlier, and would underestimate prevalence the longer 
the elapsed time since infections and outbreaks occurred. Further 
research is therefore required to understand the full spectrum of the 
innate and adaptive immune responses to SARS-CoV-2 as a function of 
time, in order to more accurately model the effect of waning antibody 
levels or absence of seroconversion on estimations of past infections 
in a given population. This would in turn allow the population-
level susceptibility (currently assumed by models to be 100%) to be 
determined from actual data and would also affect calculation of the 
effective reproductive rate of the virus. For population-level serological 
testing, optimising the testing strategy for specificity is required, to 
minimise false positives in low-prevalence settings (Box  2), and a 
two-test strategy may need to be implemented for all positive cases to 
reduce the impact of type 1 errors on the seroprevalence data.
Can we detect re-infection and protective immunity?
Humoral responses to other beta-coronaviruses vary, with neutrali-
sing antibody responses to SARS-CoV-1 detectable in certain 
individuals with severe disease several years after infection.[16] 
In contrast, re-infection with ‘common cold’ alpha- and beta-
coronaviruses is known to occur every few years, with waning 
humoral immunity. [17] It is currently unknown what the variable 
and waning titres of antibodies against SARS-CoV-2 detected 
in serological assays might mean for re-infection or protective 
immunity as the pandemic unfolds in SA, or indeed the implications 
of this for the durability of vaccine-induced immunity. It is important 
to note, however, that rapid waning of circulating antibodies does 
not automatically mean that secondary antibody responses will not 
re-emerge upon secondary exposure – this will depend on whether 
or not a robust memory B-cell response has been generated as a result 
of the primary infection.[18] Further studies are therefore urgently 
required to understand whether there is a serological correlate of 
the development of memory B-cells, particularly those that encode 
neutralising antibodies. 
It is also worth reiterating that not all anti-S antibodies have high 
neutralising potency: a recent report showed that out of 89 patient-
derived anti-RBD (receptor-binding domain of the spike protein) 
monoclonal antibodies tested, only 58% neutralised SARS-CoV-2 
pseudovirus,[18] which means that current serological assays do not 
directly report on whether the detected antibody is neutralising. 
Therefore, no serological assay with quantitative or qualitative 
readouts can yet provide robust evidence that long-lasting protective 
immunity is present. Despite the fact that COVID-19 serological 
tests have provoked considerable interest from employers and 
governments in recent months as potential immunity passports, until 
more research has been done, we cannot stress too strongly the need 
Box 2. The importance of test specificity in seroprevalence 
studies on COVID-19
Current local regulatory clinical performance targets for COVID-
19 serological tests are minimum 85% sensitivity and 98% 
specificity.[19] To put these numbers into practical context, if the 
prevalence of SARS-CoV-2 infection in the target population 
is 1%, then for a test with these performance characteristics, 
67% of all positive results would be false positives, which would 
severely limit the utility of the data in unbiased population-level 
seroprevalence studies.  On 19 July 2020, there were ~360 000 
polymerase chain reaction-confirmed cases in SA, equating to a 
known prevalence of 0.6%; even if the true prevalence is actually 
five times higher at 3%, then ~42% of positive results would 
still be false for a test meeting those minimum requirements. So 
specificity, not sensitivity, is absolutely key for seroprevalence 
studies and really needs to be close to 100% when used in a field 
setting, unless the true disease prevalence is much higher. 
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for caution to avoid over-interpretation of antibody testing results in 
terms of likely immunity to future infection – a view also held by the 
World Health Organization.[20]
More about protective immunity: Vaccines
An important future use of ELISA-based quantitative serological 
testing is around vaccine evaluation: whether a vaccine can elicit 
immunity in immunised individuals. Testing for vaccine-induced 
immunogenicity can take the form of measuring either binding or 
neutralising antibodies, the latter being the functional antibody that 
neutralises the virus before entry into host cells. Having an antibody 
test that is both sensitive and specific to the vaccine product will be 
important, so that vaccine-induced immunity can be measured. The 
holy grail of vaccine development is to induce protective immunity in 
immunised individuals; currently there are ~170 candidate vaccines in 
development,[21] with ~27 vaccines in human clinical trials. As certain 
products enter phase III efficacy trials,[22] we will begin to understand 
what constitutes protective immunity. Is it binding or neutralising 
antibodies or is it the T-cell arm that confers protection?[23] Whatever 
the protective mechanisms might be for different vaccine products, 
antibody responses can become important correlates of protection 
and their measurement will probably be used to judge the spread of 
protective immunity in the population. Whether measurement of 
binding and/or neutralising antibodies is important in evaluating 
vaccine-induced protective immunity remains to be seen. Hopefully 
the current trials underway will provide this evidence. Either way, once 
we have established a quantitative serological correlate of immune 
protection, we can start to evaluate whether herd immunity is evolving, 
which could assist in protecting vulnerable people in our population. 
We also need to note two important caveats to vaccine-induced 
antibodies and their measurement. First, not all antibody responses may 
be protective and, theoretically, non-functional antibodies may do the 
opposite and enhance disease by antibody-dependent enhancement.[24,25] 
Being able to measure vaccine-induced antibodies (including specific 
immunoglobulin class and subclass) along with function (neutralising) 
will therefore be a critical component of future vaccine serological 
testing. Second, distinguishing natural infection from vaccine responses 
will be important in the context of identifying whether a vaccine 
response is able to provide protection from SARS-CoV-2 infection or 
whether ‘breakthrough’ infections can occur. A serological test that can 
distinguish vaccine-induced from infection-induced antibody response 
may therefore need to be based on detection of antibodies to specific 
neutralising epitopes on the S protein, or to non-S proteins, such the 
N protein (noting that the N protein would be absent in vaccines that 
only target the S protein, but would be present in live attenuated or 
killed SARS-CoV-2 formulations), or both. However, this may come 
at a cost of lower specificity, as anti-N antibodies may cross-react with 
other coronaviruses that are in common circulation.[26,27]
In conclusion, the choice, approval and use of either ELISA or 
rapid antibody testing for host immunity to SARS-CoV-2 has to be 
met with thought and scientific rigour. It is critical to pay homage 
to how the host immune system interacts with acute viral infections 
and to become informed around the complex interplay between 
viral antigens, timing of infection, antibody function and testing 
utility. Antibody testing for SARS-CoV-2 should not be thought of as 
diagnostic or prognostic, but as a precious tool to evaluate population 
immunity to natural infection, as a valuable research tool, and as a 
correlate of vaccine-induced protection.
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